Barclays PLC Sana Biotechnology, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Barclays PLC holds 318,910 shares of SANA stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

318,910

Previous 318,910 -0.0%

Holding current value

$1.03 Million

Previous $1.33 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.76 - $6.86 $669,953 - $1.22 Million	178,179 Added 126.61%	318,910 $1.33 Million
Q2 2024 Aug 14, 2024	BUY	$5.23 - $10.44 $129,285 - $258,076	24,720 Added 21.31%	140,731 $769,000
Q1 2024 May 15, 2024	SELL	$4.2 - $11.27 $985,332 - $2.64 Million	-234,603 Reduced 66.91%	116,011 $1.16 Million
Q4 2023 Feb 15, 2024	BUY	$2.8 - $4.55 $406,131 - $659,963	145,047 Added 70.56%	350,614 $1.43 Million
Q3 2023 Nov 07, 2023	BUY	$3.77 - $6.23 $22,981 - $37,978	6,096 Added 3.06%	205,567 $797,000
Q2 2023 Aug 03, 2023	SELL	$3.22 - $7.53 $55,953 - $130,848	-17,377 Reduced 8.01%	199,471 $1.19 Million
Q1 2023 May 04, 2023	SELL	$3.11 - $4.92 $268,274 - $424,409	-86,262 Reduced 28.46%	216,848 $710,000
Q4 2022 Feb 13, 2023	BUY	$3.19 - $6.46 $31,526 - $63,844	9,883 Added 3.37%	303,110 $1.2 Million
Q3 2022 Nov 03, 2022	BUY	$5.58 - $9.04 $1.47 Million - $2.39 Million	264,030 Added 904.31%	293,227 $1.76 Million
Q2 2022 Aug 12, 2022	SELL	$4.12 - $9.35 $85,502 - $194,040	-20,753 Reduced 41.55%	29,197 $188,000
Q1 2022 May 16, 2022	BUY	$5.24 - $15.58 $261,738 - $778,221	49,950 New	49,950 $412,000

Others Institutions Holding SANA

# of Institutions

172

Shares Held

121M

Call Options Held

1.87M

Put Options Held

1.48M

View Full List

About Sana Biotechnology, Inc.

Ticker SANA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 190,232,000
Market Cap $613M
Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...

More about SANA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account